Losartan
لوزارتان
❤️ Cardiovascular SystemAngiotensin receptor blocker
Market / country: 🇺🇸 USA
Cozaar (US)
🧮 Dose calculator
Hypertension · Regimen source: FDA Losartan · 2.1FDA Losartan · 8.4
- • Adjust to blood pressure; doses above 1.4 mg/kg or 100 mg/day not studied in children. FDA Losartan · 2.1
Enter age and weight.
🛡️ Safety & information
Contraindications
- ⛔ Hypersensitivity; coadministration with aliskiren in diabetes. FDA Losartan · 4
- ⛔ Not established under 6 years. FDA Losartan · 8.4
Warnings
- • Boxed warning: fetal toxicity; discontinue when pregnancy is detected. FDA Losartan · WARNING: FETAL TOXICITY
Renal adjustment
- • eGFR < 30: Not recommended in pediatric patients with GFR <30. FDA Losartan · 8.4
Formulations
- 25 mg tablet — tablet 🇺🇸 USA FDA Losartan · 3
- 50 mg tablet (scored) — tablet 🇺🇸 USA FDA Losartan · 3
- 100 mg tablet — tablet 🇺🇸 USA FDA Losartan · 3
👥 Special populations
- 🤰 PregnancyDangerous / avoid
Label: can cause fetal harm. Dangerous in pregnancy. FDA Losartan · Boxed Warning
“WARNING: FETAL TOXICITY See full prescribing information for complete boxed warning.”
- 🤱 BreastfeedingUse with caution
Label: use with caution while breastfeeding; see the label text. FDA Losartan · 8.2
“Because of the potential for adverse effects on the nursing infant, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.”
- 👶 ChildrenUse with caution
The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Losartan · 8.4
“Safety and effectiveness have not been established in pediatric patients under the age of 6 or in pediatric patients with glomerular filtration rate <30 mL/min/1.73 m 2 [see Dosage and Administration (2.1) , Clinical Pharmacology (12.3) , and Clinical Studies (14.1) ] .”
- 👴 Older adultsUse with caution
Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Losartan · 8.5
“In a controlled clinical study for the reduction in the combined risk of cardiovascular death, stroke and myocardial infarction in hypertensive patients with left ventricular hypertrophy, 2857 patients (62%) were 65 years and over, while 808 patients (18%) were 75 years and over.”
- ⚥ Females & males of reproductive potentialNo data
The source for this drug has no section for this group.
🔗 Reference links
- FDA (approval record)ANDA203030
- DailyMed (FDA label)FDA Losartan
- MedlinePlus (NIH)Losartan
- WHO ATC/DDDC09CA01
- Darooyab (Iran)Losartan
🇮🇷 Registered in Iran Darooyab · G-1743/Losartan
Dosage forms with Iranian generic codes, per Darooyab.
- 06214 · LOSARTAN 20MG CAP · کپسول لوزارتان ۲۰ میلیگرم
- 12796 · LOSARTAN POTASSIUM 100MG TAB · قرص لوزارتان پتاسیم ۱۰۰ میلیگرم
- 01822 · LOSARTAN POTASSIUM 25MG TAB · قرص لوزارتان پتاسیم ۲۵ میلیگرم
- 01933 · LOSARTAN POTASSIUM 50MG TAB · قرص لوزارتان پتاسیم ۵۰ میلیگرم
📚 Reference status for this drug
Shows which sources have references recorded for this drug and which do not.
- FDA label (DailyMed)✅ PresentFDA Losartan · 3FDA Losartan · 2.1FDA Losartan · 8.4FDA Losartan · 4FDA Losartan · WARNING: FETAL TOXICITYFDA Losartan · Boxed WarningFDA Losartan · 8.2FDA Losartan · 8.5FDA Losartan · SPL approval / marketing category
- UK SmPC (eMC / MHRA)❌ Not present
- Published guideline❌ Not present
- Licensed reference (medical school)❌ Not present
- Iranian leaflet (IFDA)❌ Not present
- Pharmacy website (secondary, unreliable)✅ PresentDarooyab · G-1743/Losartan
- Clinical review⚠ Unverified